Radiotherapy Clinical Trial
Official title:
Combination of Immune Checkpoint Inhibitors PD-1 Monoclonal Antibody and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Retrospective Cohort Study
This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical carcinomas. Patients may or may not accept PD-1 antibody as maintenance therapy. Patients are followed up and the survival outcomes are evaluated. The primary endpoint are objective remission rate. The secondary endpoints are progression-free survival, overall survival and severe adverse events.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03212742 -
Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06190782 -
Local Therapy for Oligometastatic Esophageal Squamous Cell Cancer Patients Treated With PD-1 Inhibitor: a Prospective, Randomized, Phase III Clinical Trial.
|
Phase 3 | |
| Recruiting |
NCT06120127 -
Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
|
Phase 2 | |
| Recruiting |
NCT05176002 -
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05909137 -
Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
|
||
| Recruiting |
NCT02661152 -
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.
|
Phase 3 | |
| Withdrawn |
NCT02542137 -
Abscopal Effect for Metastatic Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01212731 -
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
|
||
| Completed |
NCT01168479 -
FLAME: Investigate the Benefit of a Focal Lesion Ablative Microboost in Prostate Cancer
|
Phase 3 | |
| Recruiting |
NCT03658343 -
T2* MRI Analysis for Sarcoma
|
N/A | |
| Completed |
NCT03280719 -
Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions
|
N/A | |
| Recruiting |
NCT05514327 -
A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL
|
N/A | |
| Recruiting |
NCT05515796 -
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
|
Phase 2 | |
| Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
| Recruiting |
NCT03370926 -
FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy
|
N/A | |
| Active, not recruiting |
NCT03870919 -
Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients
|
N/A | |
| Active, not recruiting |
NCT02428049 -
Radiation Pneumonitis After SBRT for NSCLC
|
||
| Recruiting |
NCT04923620 -
Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy
|
||
| Active, not recruiting |
NCT05371795 -
Comparison on Radiotherapy Permanent Skin Marking With Lancets and an Electric Marking Device
|
N/A | |
| Recruiting |
NCT03210428 -
Quantitative MR Imaging in Locally Advanced Cervical Cancer
|